IP Library Granted Patent US 9,616,113
Granted Patent B2
US 9,616,113 · App. 14/624,463 · Granted Apr 11, 2017

Peptide conjugated particles

Inventors: Lonnie D. Shea (Evanston, IL); Stephen D. Miller (Evanston, IL); Jonathan Woon Teck Yap (Evanston, IL); Daniel R. Getts (Washington, DC); Derrick McCarthy (Evanton, IL)
Assignee: NORTHWESTERN UNIVERSITY
A61K39/0008A61K9/1647A61K9/19A61K39/00A61K47/48815A61K47/48907A61K47/48915A61K9/5153A61K2039/55555A61K2039/577A61K2039/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,616,113
App. No.
14/624,463
Granted
Apr 11, 2017
Kind
B2
Abstract

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).

Claims (13)

1. A composition comprising surface functionalized biodegradable PLG particles comprising encapsulated gliaden or one or more antigenic epitopes thereof wherein said PLG particles have a copolymer ratio of about 50:50 poly(lactide-co-glycolide), a diameter of about 400 nm to about 800 nm and a zeta potential of about −75 mV to about −50 mV.

2. The composition of claim 1 , wherein the gliadin or one or more antigenic gliaden epitopes comprises one or more of the sequences set forth in SEQ ID NOS: 1295-1724, 1726-1766, and 4983-5440.

3. The composition of claim 1 , wherein the particles have a zeta potential of about −50 mV.

4. The composition of claim 1 , wherein the particles have a diameter of about 600 nm.

5. The composition of claim 1 , further comprising pharmaceutically acceptable excipients.

6. The particles of claim 1 wherein the surface functionalization is carboxylation.

7. The composition of claim 6 wherein the carboxylation is achieved by using poly(ethylene-maleic anhydride) (PEMA).

8. A lyophilized composition comprising surface functionalized biodegradable poly(lactide-co-glycolide)(PLG) particles comprising encapsulated gliaden or one or more antigenic gliaden epitopes, wherein said PLG particles have a copolymer ratio of about 50:50 poly(lactide-co-glycolide), a diameter of about 400 nm to about 1100 nm and a zeta potential of about 75 mV to about −50 mV.

9. The lyophilized composition of claim 8 wherein the one or more antigenic gliaden epitopes comprises one or more of the sequences set forth in SEQ ID NOS: 1295-1724, 1726-1766, and 4983-5440.

10. The lyophilized composition of claim 8 , wherein the surface functionalization is carboxylation.

11. The lyophilized composition of claim 10 wherein the carboxylation is achieved by using poly(ethylene-maleic anhydride) (PEMA).

12. The lyophilized composition of claim 8 , wherein the particles have a zeta potential of about −70 mV.

13. The lyophilized composition of claim 8 , wherein the particles have a diameter of about 1100 nm.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 1, 2015
From: NORTHWESTERN UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036053/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2015
From: SHEA, LONNIE D.; MILLER, STEPHEN DOUGLAS; YAP, JONATHAN WOON TECK; GETTS, DANIEL R.; MCCARTHY, DERRICK
To: NORTHWESTERN UNIVERSITY
Reel/Frame 035957/0308 →
Continuity (5)
Continuation PCTUS2014050962 · Aug 13, 2014
Provisional Application 61865389 · Aug 13, 2013
Provisional Application 61869279 · Aug 23, 2013
Provisional Application 61887112 · Oct 4, 2013
Related Publication 20150190485A1 · Jul 9, 2015